A young boy's nightmare diagnosis, and the $3 million one-time treatment that will likely save his life

The groundbreaking treatment is one of six gene therapies cleared since 2017 that have transformed the outlook for disorders once considered hopeless — and also renewed questions about how the health care system can afford such breathtakingly expensive medicines.

Related Keywords

United States ,Boston ,Massachusetts ,Philadelphia ,Pennsylvania ,Tufts Medical Center ,New York ,Brooklyn ,University Of Pennsylvania ,Watertown ,Michael Sherman ,Jess Rowlands ,Florian Eichler ,Adam Hess ,Darcy Gray ,Conner Hess ,Edward Kaye ,Christine Duncan ,Daniel Ollendorf ,Glynda Jackson ,Andrew Obenshain ,Ezekial Emanuel ,Elisa Seeger ,Aidan Seeger ,Lorenzo Oil ,Drug Administration ,Massachusetts Association Of Health ,Novartis ,Duke University ,University Of Minnesota Masonic Children Hospital ,Department Of Public Health ,Alliance For Regenerative Medicine ,Tufts Center ,Risk In Health ,Richelle Brooks ,Boston Children ,Bluebird Bio ,Northern Ireland ,Massachusetts General Hospital ,Regenerative Medicine ,Stoke Therapeutics ,Minnesota Masonic Children ,Massachusetts Association ,Health Plans ,Public Health , ,